The company was founded in 2014 and is committed to developing effective and non-addictive medicines for chronic pain and other chronic inflammatory and neurodegenerative disorders. BioIntervene's founding team has pioneered the understanding of adenosine A3 receptor biology, with a focus on developing first-in-class, selective adenosine A3 receptor agonists. Their goal is to develop first-in-class and selective A3 adenosine receptor analgesics to treat neuropathic pain and other related problems, providing pharmaceutical companies with new options for treating neuro pains and other related problems.